Table 1 Baseline patient demographics and disease characteristics
CT-P13 3 mg/kg (n = 302) | RP 3 mg/kg (n = 304) | Total (N = 606) | |
|---|---|---|---|
Age, median, years (range) | 50 (18–75) | 50 (21–74) | 50 (18–75) |
Sex, n (%) | |||
Female | 245 (81.1) | 256 (84.2) | 501 (82.7) |
Male | 57 (18.9) | 48 (15.8) | 105 (17.3) |
Ethnicity, n (%) | |||
Asian | 34 (11.3) | 37 (12.2) | 71 (11.7) |
Black | 2 (0.7) | 1 (0.3) | 3 (0.5) |
White | 220 (72.8) | 222 (73.0) | 442 (72.9) |
Other | 46 (15.2) | 44 (14.5) | 90 (14.9) |
Height, cm, median (range) | 162.3 (144.0–186.0) | 162.0 (124.0–190.0) | 162.0 (124.0–190.0) |
Weight, kg, median (range) | 69.0 (36.5–134.0) | 68.0 (36.0–136.0) | 68.6 (36.0–136.0) |
BMI, kg/m2, median (range) | 26.3 (13.9–49.8) | 25.4 (15.0–53.1) | 25.9 (13.9–53.1) |
Anti-CCP antibody-positive, n (%) | 228 (75.5) | 233 (76.6) | 461 (76.1) |
IgA RF-positive, n (%) | 131 (43.4) | 134 (44.1) | 265 (43.7) |
IgM RF-positive, n (%) | 225 (74.5) | 220 (72.4) | 445 (73.4) |
IgG RF-positive, n (%) | 173 (57.3) | 171 (56.3) | 344 (56.8) |
Joint count | |||
TJC, 68 joints | 25.6 ± 13.9 | 24.0 ± 12.9 | 24.8 ± 13.4 |
SJC, 66 joints | 16.2 ± 8.7 | 15.2 ± 8.3 | 15.7 ± 8.5 |
TJC, 28 joints | 15.9 ± 6.4 | 15.1 ± 6.1 | 15.5 ± 6.2 |
SJC, 28 joints | 12.0 ± 4.9 | 11.2 ± 4.7 | 11.6 ± 4.8 |
Duration of prior MTX therapy, weeks | 97.7 ± 141.2 | 89.4 ± 96.5 | 93.6 ± 120.8 |
MTX dose, mg | 15.6 ± 3.1 | 15.6 ± 3.2 | 15.6 ± 3.1 |
CDAI | 40.9 ± 11.5 | 39.3 ± 11.1 | 40.1 ± 11.3 |
SDAI | 42.8 ± 11.9 | 41.2 ± 11.7 | 42.0 ± 11.8 |
CRP, mg/dl | 1.9 ± 2.5 | 1.9 ± 2.2 | 1.9 ± 2.4 |
ESR, mm/h | 46.6 ± 22.4 | 48.5 ± 22.6 | 47.5 ± 22.5 |
DAS28-CRP | 5.9 ± 0.8 | 5.8 ± 0.9 | 5.8 ± 0.9 |
HAQ | 1.6 ± 0.6 | 1.6 ± 0.6 | 1.6 ± 0.6 |
Patient assessment of pain | 65.9 ± 17.4 | 65.5 ± 17.2 | 65.7 ± 17.3 |
Patient global assessment of disease activity | 65.7 ± 17.2 | 65.4 ± 17.0 | 65.5 ± 17.1 |
Physician global assessment of disease activity | 64.7 ± 14.3 | 65.0 ± 13.5 | 64.8 ± 13.9 |